Erleada (apalutamide) is not a chemotherapy drug. It is an androgen receptor inhibitor, a type of hormone therapy used to treat prostate cancer. While chemotherapy works by killing rapidly dividing cells throughout the body, Erleada works by blocking testosterone from fueling prostate cancer growth. The distinction matters because the two treatments differ significantly in how they’re taken, how they feel, and what side effects they cause.
How Erleada Works
Prostate cancer cells rely on male hormones called androgens, primarily testosterone, to grow. These hormones attach to androgen receptors on the surface of cancer cells, essentially flipping a switch that tells the cell to multiply. Erleada binds directly to those same receptors and blocks testosterone from reaching them. Without that hormonal signal, cancer cells slow their growth and begin to die off.
This is fundamentally different from how chemotherapy operates. Traditional chemo drugs like docetaxel are cytotoxic, meaning they poison cells that are actively dividing. That’s why chemo causes hair loss, nausea, and immune suppression: it damages healthy fast-growing cells along with cancerous ones. Erleada doesn’t work this way. It targets a specific hormonal pathway rather than attacking cell division broadly, which is why its side effect profile looks nothing like chemotherapy.
What Erleada Is Approved to Treat
The FDA has approved Erleada for two specific types of prostate cancer:
- Metastatic castration-sensitive prostate cancer (mCSPC): cancer that has spread beyond the prostate but still responds to hormone-lowering treatments.
- Non-metastatic castration-resistant prostate cancer (nmCRPC): cancer that hasn’t spread but is no longer responding to standard hormone therapy.
In both cases, Erleada is taken alongside another form of hormone suppression, typically an injection that lowers testosterone production. The National Comprehensive Cancer Network lists apalutamide as a preferred option for hormone-sensitive metastatic prostate cancer when combined with standard androgen deprivation therapy.
How You Take It
One of the most practical differences between Erleada and chemotherapy is how it’s administered. Chemo is typically given through an IV at an infusion center, often in cycles that require hours of sitting in a clinic. Erleada is a daily pill taken at home. The standard dose is 240 mg once a day, with or without food, swallowed whole.
There are no infusion appointments, no IV lines, and no treatment cycles. You take it every day on an ongoing basis for as long as it continues to work. That daily routine is much closer to what people experience with blood pressure medication or other chronic prescriptions than what most people picture when they think of cancer treatment.
Side Effects Compared to Chemo
Erleada’s side effects are real, but they look very different from the nausea, hair loss, and severe immune suppression associated with chemotherapy. The most common side effects (occurring in at least 10% of patients) include fatigue, joint pain, rash, decreased appetite, falls, weight loss, high blood pressure, hot flashes, diarrhea, and fractures.
Skin rash is one of the more distinctive side effects. About 26% of patients develop a rash while taking Erleada, compared to 8% on placebo. In roughly 6% of cases, the rash covers more than 30% of the body and is considered severe. Fatigue is also common, affecting 39% of patients in one major trial, though it was rarely severe (about 1.4% at a serious grade). About 23% of patients in the metastatic trial needed a dose interruption or reduction, most often because of rash, fatigue, or high blood pressure.
All next-generation androgen receptor inhibitors, including Erleada, carry an increased risk of cardiovascular events and hypertension. This is worth discussing with your oncologist, especially if you already have heart disease or high blood pressure. But the overall tolerability is considerably better than cytotoxic chemotherapy, which is one reason these newer hormone therapies have become preferred earlier in the treatment pathway.
Where Erleada Fits in Prostate Cancer Treatment
Prostate cancer treatment has shifted substantially over the past decade. Chemotherapy used to be one of the few options for advanced disease, but newer hormone therapies like Erleada, enzalutamide, and abiraterone have changed the standard of care. Current guidelines now recommend these drugs as preferred first-line additions to standard hormone suppression for men with metastatic hormone-sensitive prostate cancer, often before chemotherapy is ever considered.
Chemotherapy still has a role. For men with aggressive or high-volume metastatic disease, docetaxel may be added alongside hormone therapy. And for men whose cancer progresses through multiple hormone treatments, chemo remains an important option later in the course of the disease. But Erleada itself occupies a different lane entirely. It’s a targeted hormone therapy, not a cytotoxic agent, and for many men with prostate cancer it represents a way to control the disease without the intensity of a traditional chemotherapy regimen.